Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1997;24(4):260–268.

Update on pediatric heart transplantation. Long-term complications.

R J Gajarski 1, D L Kearney 1, J K Price 1, S W Denfield 1
PMCID: PMC325467  PMID: 9456478

Abstract

Despite evolution to "higher-order" immunosuppressive agents that better control cell-mediated allograft rejection and, therefore, short- and intermediate-term survival, allograft vasculopathy and PTLD remain factors that limit extended graft survival. While improved basic science "bench" techniques have enabled investigation of their pathogenesis at the subcellular and molecular levels, each scientific advance leads the way to the next horizon of complex questions. Only through a more complete understanding of the etiology and pathophysiology of these processes will we be able to design strategies to combat these complications.

Full text

PDF
260

Images in this article

263Image
on p.263
263Image
on p.263
263Image
on p.263
264Image
on p.264
265Image
on p.265
265Image
on p.265

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckman J. S., Beckman T. W., Chen J., Marshall P. A., Freeman B. A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1620–1624. doi: 10.1073/pnas.87.4.1620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Benditt E. P. Implications of the monoclonal character of human atherosclerotic plaques. Ann N Y Acad Sci. 1976;275:96–100. doi: 10.1111/j.1749-6632.1976.tb43342.x. [DOI] [PubMed] [Google Scholar]
  3. Bernstein D., Baum D., Berry G., Dahl G., Weiss L., Starnes V. A., Gamberg P., Stinson E. B. Neoplastic disorders after pediatric heart transplantation. Circulation. 1993 Nov;88(5 Pt 2):II230–II237. [PubMed] [Google Scholar]
  4. Briscoe D. M., Schoen F. J., Rice G. E., Bevilacqua M. P., Ganz P., Pober J. S. Induced expression of endothelial-leukocyte adhesion molecules in human cardiac allografts. Transplantation. 1991 Feb;51(2):537–539. [PubMed] [Google Scholar]
  5. Canter C. E., Saffitz J. E., Moorhead S., Gutierrez F. R., Bolman R. M., Spray T. L. Early results after pediatric cardiac transplantation with triple immunosuppression therapy. Am J Cardiol. 1993 Apr 15;71(11):971–975. doi: 10.1016/0002-9149(93)90916-z. [DOI] [PubMed] [Google Scholar]
  6. Chenzbraun A., Pinto F. J., Alderman E. L., Botas J., Oesterle S. N., Schroeder J. S., Valantine H., Popp R. L. Distribution and morphologic features of coronary artery disease in cardiac allografts: an intracoronary ultrasound study. J Am Soc Echocardiogr. 1995 Jan-Feb;8(1):1–8. doi: 10.1016/s0894-7317(05)80351-7. [DOI] [PubMed] [Google Scholar]
  7. Costanzo M. R. The role of histoincompatibility in cardiac allograft vasculopathy. J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S180–S184. [PubMed] [Google Scholar]
  8. Crisp S. J., Dunn M. J., Rose M. L., Barbir M., Yacoub M. H. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease? J Heart Lung Transplant. 1994 Jan-Feb;13(1 Pt 1):81–92. [PubMed] [Google Scholar]
  9. Day J. D., Rayburn B. K., Gaudin P. B., Baldwin W. M., 3rd, Lowenstein C. J., Kasper E. K., Baughman K. L., Baumgartner W. A., Hutchins G. M., Hruban R. H. Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S142–S149. [PubMed] [Google Scholar]
  10. Dayton J. S., Turka L. A., Thompson C. B., Mitchell B. S. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol. 1992 Apr;41(4):671–676. [PubMed] [Google Scholar]
  11. Ensley R. D., Bristow M. R., Olsen S. L., Taylor D. O., Hammond E. H., O'Connell J. B., Dunn D., Osburn L., Jones K. W., Kauffman R. S. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation. 1993 Jul;56(1):75–82. doi: 10.1097/00007890-199307000-00013. [DOI] [PubMed] [Google Scholar]
  12. Fricker F. J., Griffith B. P., Hardesty R. L., Trento A., Gold L. M., Schmeltz K., Beerman L. B., Fischer D. R., Mathews R. A., Neches W. H. Experience with heart transplantation in children. Pediatrics. 1987 Jan;79(1):138–146. [PubMed] [Google Scholar]
  13. Grusby M. J., Auchincloss H., Jr, Lee R., Johnson R. S., Spencer J. P., Zijlstra M., Jaenisch R., Papaioannou V. E., Glimcher L. H. Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci U S A. 1993 May 1;90(9):3913–3917. doi: 10.1073/pnas.90.9.3913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Heroux A. L., Silverman P., Costanzo M. R., O'Sullivan E. J., Johnson M. R., Liao Y., McKiernan T. L., Balhan J. E., Leya F. S., Mullen G. M. Intracoronary ultrasound assessment of morphological and functional abnormalities associated with cardiac allograft vasculopathy. Circulation. 1994 Jan;89(1):272–277. doi: 10.1161/01.cir.89.1.272. [DOI] [PubMed] [Google Scholar]
  15. Hosenpud J. D., Novick R. J., Breen T. J., Keck B., Daily P. The Registry of the International Society for Heart and Lung Transplantation: twelfth official report--1995. J Heart Lung Transplant. 1995 Sep-Oct;14(5):805–815. [PubMed] [Google Scholar]
  16. Johnson J. A., Kobashigawa J. A. Quantitative analysis of transplant coronary artery disease with use of intracoronary ultrasound. J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S198–S202. [PubMed] [Google Scholar]
  17. Jost S., Rafflenbeul W., Deckers J., Wiese B., Hecker H., Nikutta P., Lippolt P., Lichtlen P. Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators. Eur J Epidemiol. 1992 May;8 (Suppl 1):107–119. doi: 10.1007/BF00145361. [DOI] [PubMed] [Google Scholar]
  18. Kemna M. S., Valantine H. A., Hunt S. A., Schroeder J. S., Chen Y. D., Reaven G. M. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J. 1994 Jul;128(1):68–72. doi: 10.1016/0002-8703(94)90011-6. [DOI] [PubMed] [Google Scholar]
  19. Kobashigawa J. A., Miller L., Yeung A., Hauptman P., Ventura H., Wilensky R., Valantine H., Wiedermann J. Does acute rejection correlate with the development of transplant coronary artery disease? A multicenter study using intravascular ultrasound. Sandoz/CVIS Investigators. J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S221–S226. [PubMed] [Google Scholar]
  20. Kobayashi J., Crawford S. E., Backer C. L., Zales V. R., Takami H., Hsueh C., Huang L., Mavroudis C. Captopril reduces graft coronary artery disease in a rat heterotopic transplant model. Circulation. 1993 Nov;88(5 Pt 2):II286–II290. [PubMed] [Google Scholar]
  21. Land W., Schneeberger H., Schleibner S., Illner W. D., Abendroth D., Rutili G., Arfors K. E., Messmer K. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation. 1994 Jan;57(2):211–217. doi: 10.1097/00007890-199401001-00010. [DOI] [PubMed] [Google Scholar]
  22. Latson L. A., Tuzcu E. M., Nissen S. Coronary intravascular ultrasound in 2 children after cardiac transplantation. Tex Heart Inst J. 1994;21(4):310–313. [PMC free article] [PubMed] [Google Scholar]
  23. Mehra M. R., Ventura H. O., Smart F. W., Collins T. J., Ramee S. R., Stapleton D. D. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol. 1995 Apr 15;75(12):853–854. doi: 10.1016/s0002-9149(99)80432-9. [DOI] [PubMed] [Google Scholar]
  24. Mehra M. R., Ventura H. O., Smart F. W., Stapleton D. D. Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: from bench to bedside. J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S246–S249. [PubMed] [Google Scholar]
  25. Millane T., Wilson A. J., Patel M. K., Jennison S. H., Holt D. W., Murday A. J., Camm A. J. Mitochondrial calcium deposition in association with cyclosporine therapy and myocardial magnesium depletion: a serial histologic study in heart transplant recipients. J Heart Lung Transplant. 1994 May-Jun;13(3):473–480. [PubMed] [Google Scholar]
  26. Miller L., Kobashigawa J., Valantine H., Ventura H., Hauptman P., O'Donnell J., Wiedermann J., Yeung A. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. Sandoz/CVIS Investigators. J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S227–S234. [PubMed] [Google Scholar]
  27. Morris R. E. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant. 1993 Nov-Dec;12(6 Pt 2):S275–S286. [PubMed] [Google Scholar]
  28. Nayler W. G., Gu X. H. Protecting the vasculature: an eye toward the future. Am J Cardiol. 1990 Nov 20;66(18):23H–27H. doi: 10.1016/0002-9149(90)90572-i. [DOI] [PubMed] [Google Scholar]
  29. Pahl E., Zales V. R., Fricker F. J., Addonizio L. J. Posttransplant coronary artery disease in children. A multicenter national survey. Circulation. 1994 Nov;90(5 Pt 2):II56–II60. [PubMed] [Google Scholar]
  30. Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant. 1993 Nov-Dec;12(6 Pt 2):S328–S336. [PubMed] [Google Scholar]
  31. Powell J. S., Clozel J. P., Müller R. K., Kuhn H., Hefti F., Hosang M., Baumgartner H. R. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989 Jul 14;245(4914):186–188. doi: 10.1126/science.2526370. [DOI] [PubMed] [Google Scholar]
  32. Radovancevic B., Poindexter S., Birovljev S., Velebit V., McAllister H. A., Duncan J. M., Vega D., Lonquist J., Burnett C. M., Frazier O. H. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg. 1990;4(6):309–313. doi: 10.1016/1010-7940(90)90207-g. [DOI] [PubMed] [Google Scholar]
  33. Rickenbacher P. R., Pinto F. J., Chenzbraun A., Botas J., Lewis N. P., Alderman E. L., Valantine H. A., Hunt S. A., Schroeder J. S., Popp R. L. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol. 1995 Jan;25(1):171–177. doi: 10.1016/0735-1097(94)00323-i. [DOI] [PubMed] [Google Scholar]
  34. Ross R. Mechanisms of atherosclerosis--a review. Adv Nephrol Necker Hosp. 1990;19:79–86. [PubMed] [Google Scholar]
  35. Slaughter M. S., Braunlin E., Bolman R. M., 3rd, Molina J. E., Shumway S. J. Pediatric heart transplantation: results of 2- and 5-year follow-up. J Heart Lung Transplant. 1994 Jul-Aug;13(4):624–630. [PubMed] [Google Scholar]
  36. Starzl T. E., Nalesnik M. A., Porter K. A., Ho M., Iwatsuki S., Griffith B. P., Rosenthal J. T., Hakala T. R., Shaw B. W., Jr, Hardesty R. L. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984 Mar 17;1(8377):583–587. doi: 10.1016/s0140-6736(84)90994-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sullivan J. L., Medveczky P., Forman S. J., Baker S. M., Monroe J. E., Mulder C. Epstein-Barr-virus induced lymphoproliferation. Implications for antiviral chemotherapy. N Engl J Med. 1984 Nov 1;311(18):1163–1167. doi: 10.1056/NEJM198411013111806. [DOI] [PubMed] [Google Scholar]
  38. Uchino T., Belboul A., el-Gatit A., Roberts D., Berglin E., William-Olsson G. Assessment of myocardial damage by circulating cardiac myosin light chain I after heart transplantation. J Heart Lung Transplant. 1994 May-Jun;13(3):418–423. [PubMed] [Google Scholar]
  39. Uretsky B. F., Murali S., Reddy P. S., Rabin B., Lee A., Griffith B. P., Hardesty R. L., Trento A., Bahnson H. T. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987 Oct;76(4):827–834. doi: 10.1161/01.cir.76.4.827. [DOI] [PubMed] [Google Scholar]
  40. Valantine H. A. Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S234–S237. [PubMed] [Google Scholar]
  41. Young J. B. Fish oil and antioxidants after heart transplantation: future strategies or eye of newt and wing of bat revisited? J Heart Lung Transplant. 1995 Nov-Dec;14(6 Pt 2):S250–S254. [PubMed] [Google Scholar]
  42. van Es A., Baldwin W. M., Oljans P. J., Tanke H. J., Ploem J. S., van Es L. A. Expression of HLA-DR on T lymphocytes following renal transplantation, and association with graft-rejection episodes and cytomegalovirus infection. Transplantation. 1984 Jan;37(1):65–69. doi: 10.1097/00007890-198401000-00018. [DOI] [PubMed] [Google Scholar]
  43. van den Helder T. B., Benhaim P., Anthony J. P., McCalmont T. H., Mathes S. J. Efficacy of RS-61443 in reversing acute rejection in a rat model of hindlimb allotransplantation. Transplantation. 1994 Feb;57(3):427–433. doi: 10.1097/00007890-199402150-00020. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES